



Molecular Characteristics of Cerebral Ischemia and Their Therapeutic Applications

Guest Editors:

Dr. E-Jian Lee

Neurophysiology Laboratory,
Neurosurgical Service,
Department of Surgery, National
Cheng Kung University Hospital,
College of Medicine, National
Cheng Kung University, Tainan
70403, Taiwan

Dr. Shengyang Huang

Neurophysiology Laboratory,
Neurosurgical Service,
Department of Surgery, National
Cheng Kung University Hospital,
College of Medicine, National
Cheng Kung University, Tainan
70403, Taiwan

Message from the Guest Editors

Dear Colleagues,

This Special Issue entitled "Molecular Characteristics of Cerebral Ischemia and Their Therapeutic Applications" delves into the intricate molecular aspects associated with cerebral ischemia and explores innovative therapeutic approaches including insights into pathophysiology, biomarkers, and novel treatment strategies. Based on your previous publications and expertise in this field of research, we would like to invite you to publish your work in this Special Issue.

Dr. E-Jian Lee

Dr. Shengyang Huang

Guest Editors

Deadline for manuscript
submissions:

31 August 2024



mdpi.com/si/197311

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)